Grace Therapeutics (GRCE) Projected to Release Quarterly Earnings on Tuesday

Grace Therapeutics (NASDAQ:GRCE) is projected to issue its Q1 2027 results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($0.1293) per share and revenue of $0.40 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2027 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Grace Therapeutics (NASDAQ:GRCE) last posted its earnings results on Thursday, June 18th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.17.

Grace Therapeutics Trading Up 0.5%

Shares of GRCE stock traded up $0.01 on Tuesday, reaching $2.09. The company had a trading volume of 54,616 shares, compared to its average volume of 447,524. The stock has a market cap of $34.00 million, a PE ratio of -4.35 and a beta of 0.39. The company has a 50-day moving average of $2.35 and a 200-day moving average of $3.17. Grace Therapeutics has a 12 month low of $1.79 and a 12 month high of $5.18.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. TD Cowen lowered their target price on shares of Grace Therapeutics from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Grace Therapeutics in a report on Friday, July 17th. Craig Hallum set a $4.00 price objective on shares of Grace Therapeutics in a research report on Friday, April 24th. Finally, Wall Street Zen downgraded Grace Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Grace Therapeutics presently has an average rating of “Hold” and an average target price of $6.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GRCE. SeaCrest Wealth Management LLC bought a new stake in shares of Grace Therapeutics during the third quarter worth $42,000. ADAR1 Capital Management LLC lifted its position in Grace Therapeutics by 98.4% in the 3rd quarter. ADAR1 Capital Management LLC now owns 350,450 shares of the company’s stock valued at $1,043,000 after acquiring an additional 173,823 shares in the last quarter. Cerity Partners LLC acquired a new position in Grace Therapeutics in the 4th quarter worth $1,463,000. Renaissance Technologies LLC increased its holdings in Grace Therapeutics by 53.5% during the 4th quarter. Renaissance Technologies LLC now owns 129,781 shares of the company’s stock worth $449,000 after purchasing an additional 45,220 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Grace Therapeutics in the 4th quarter valued at about $106,000. Institutional investors own 6.08% of the company’s stock.

About Grace Therapeutics

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.